Selbyville, Delaware, April 22, 2024 (GLOBE NEWSWIRE) -- D-Dimer Testing Market size is predicted to register over USD 2 billion by 2032. The increasing prevalence of conditions, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC) will drive the industry progression.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/5972
As per the Centre of Disease Control and Prevention (CDC), the number of individuals annually impacted by deep vein thrombosis (DVT) or pulmonary embolism (PE) reached 900,000 people in the U.S. These conditions often necessitate D-Dimer testing as part of the diagnostic process to assess the likelihood of thrombotic events. The rising aging population, associated with obesity and sedentary habits, is also contributing to the growing incidence of thrombotic disorders.
Rising advancements in healthcare infrastructure, particularly in emerging economies, are boosting accessibility to diagnostic services, including D-Dimer testing. There is a growing awareness among healthcare professionals about the utility of this testing in diagnosing thrombotic disorders at an early stage. The integration of novel technologies, such as point-of-care testing and automation in laboratory settings to enhance the efficiency and accuracy of D-Dimer assays will add to the market gains.
Rising usage to treat pulmonary embolism
D-Dimer testing market from the pulmonary embolism (PE) application segment is slated to record high demand by 2032, as it represents a life-threatening condition characterized by the blockage of arteries in the lungs, often resulting from blood clots originating in other body parts. D-Dimer testing helps in the assessment of suspected cases of pulmonary embolism, aiding clinicians in ruling out or confirming the presence of thrombotic events. The rising incidence of prolonged immobility, surgery, and certain medical conditions will also contribute to the increased demand for PE diagnosis.
Growing presence in hospitals
The hospitals segment in the D-dimer testing market is poised to generate notable revenues during 2024 and 2032, due to their higher popularity as primary hubs for patient care, diagnosis, and treatment. With rising burden of thrombotic disorders globally, hospitals witness a steady influx of patients with symptoms like deep vein thrombosis (DVT) and pulmonary embolism. Hospitals also often house advanced laboratory facilities equipped with automated testing platforms and skilled personnel for facilitating efficient and high-throughput D-Dimer testing.
Asia Pacific to emerge as a lucrative market
The Asia Pacific D-dimer testing market is touted to surge at a rapid pace from 2024 to 2032, attributed to the increasing adoption of western lifestyle habits coupled with rising urbanization and sedentary lifestyles. The expanding geriatric population across Asia Pacific countries, particularly in Japan, China, and India, is predisposed to a higher incidence of thrombotic events. The improving healthcare infrastructure and growing investments in medical R&D activities in countries like South Korea and Singapore are facilitating greater accessibility to advanced diagnostic technologies.
Request for Report Customization @ https://www.gminsights.com/roc/5972
D-Dimer Testing Industry Participants
Some major companies in the global D-Dimer testing market include Siemens Healthcare GmbH, Abbott Laboratories, Thermo Fisher Scientific Inc., BioMedica Diagnostics, Unbound Medicine Inc biomérieux SA, Quidel Corporation, Diazyme Laboratories Inc. (General Atomics), FHoffmann-La Roche Ltd., HORIBA Ltd., Sekisui Diagnostics LLC (Sekisui Chemical Co. Ltd.), and Werfen.
These firms are focusing on partnership ventures to widen their global presence and customer base. For instance, in May 2022, the assay, developed by Horiba Medical, successfully detected venous thromboembolism (VTE) with excellent accuracy, reliability, and turnaround time on the manufacturer's Yumizen G800 fully automated hemostasis analyzer.
Partial Table of Contents (ToC) of the report:
Chapter 2 Executive Summary
2.1 D-dimer testing market industry 3600synopsis, 2018 - 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Testing method trends
2.1.4 Application trends
2.1.5 End-use trends
Chapter 3 D-dimer Testing Industry Insights
3.1 Industry segmentation
3.2 Industry ecosystem analysis
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Growing prevalence of blood clotting related genetic disorders
3.3.1.2 Technological advancements regarding D-dimer testing
3.3.1.3 Increasing demand for next-generation point-of-care (POC) D-dimer tests
3.3.1.4 Government initiatives towards generating awareness regarding blood clotting disorders
3.3.2 Industry pitfalls & challenges
.3.3.2.1. Lack of trained healthcare professionals
3.3.2.2 Stringent reimbursement scenario
3.4 Growth potential analysis
3.4.1 By testing method
3.4.2 By application
3.4.3 By end-use
3.5 COVID- 19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Porter's analysis
3.8 PESTEL analysis
Browse Our Reports Store - GMIPulse @ https://www.gminsights.com/gmipulse
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
